T. Bell

发表

Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia

M. Graham, R. Crooke, B. Baker, 2015 .

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Dietary Fat–Induced Alterations in Atherosclerosis Are Abolished by ACAT2-Deficiency in ApoB100 Only, LDLr−/− Mice

J. Sawyer, L. Rudel, Martha D. Wilson, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice[S]

Richard G. Lee, M. Graham, R. Crooke, 2011, Journal of Lipid Research.

Antisense Oligonucleotide-Mediated Silencing of Mitochondrial Fusion and Fission Factors Modulates Mitochondrial Dynamics and Rescues Mitochondrial Dysfunction

Shuling Guo, M. Aghajan, Andrew F. Powers, 2021, Nucleic acid therapeutics.

Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events

W. Kiosses, P. Tobias, L. Curtiss, 2008, The Journal of experimental medicine.

Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.

A. J. Donner, M. Graham, R. Crooke, 2018, Nucleic acid therapeutics.

Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein

Richard G. Lee, S. Booten, M. Graham, 2013, Journal of Lipid Research.

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Christopher E. Hart, S. Mukhopadhyay, S. Crooke, 2019, Nature Biotechnology.

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice

A. J. Donner, R. Crooke, A. Mullick, 2021, Journal of lipid research.

Monounsaturated fatty acyl-coenzyme A is predictive of atherosclerosis in human apoB-100 transgenic, LDLr−/− mice Published, JLR Papers in Press, February 4, 2007.

J. Sawyer, L. Rudel, Martha D. Wilson, 2007, Journal of Lipid Research.

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Christopher E. Hart, S. Mukhopadhyay, S. Crooke, 2019, Nature Biotechnology.

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr−/− mice

Richard G. Lee, M. Graham, R. Crooke, 2013, Journal of Lipid Research.

Antisense Oligonucleotide Inhibition of Cholesteryl Ester Transfer Protein Enhances Reverse Cholesterol Transport in Hyperlipidemic CETP Transgenic , LDLr-/-Mice

Richard G. Lee, M. Graham, R. Crooke, 2013 .

Targeted Depletion of Hepatic ACAT2-driven Cholesterol Esterification Reveals a Non-biliary Route for Fecal Neutral Sterol Loss*

Thomas L. Smith, Mark J Graham, Richard G. Lee, 2008, Journal of Biological Chemistry.

Liver-Specific Inhibition of Acyl-Coenzyme A:Cholesterol Acyltransferase 2 With Antisense Oligonucleotides Limits Atherosclerosis Development in Apolipoprotein B100–Only Low-Density Lipoprotein Receptor−/− Mice

J. M. Brown, M. Graham, R. Crooke, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr−/− mice

Richard G. Lee, M. Graham, R. Crooke, 2013, Journal of Lipid Research.

Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events

W. Kiosses, P. Tobias, L. Curtiss, 2008, The Journal of experimental medicine.